Clinical Trial Update: MANDARIN (S6371) [Phase 3]

View source ↗

Summary

Phase 3 Clinical Trial update for MANDARIN (S6371) in inoperable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MANDARIN (S6371)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Inoperable Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED